深夜福利站 Researcher Patrick O鈥橠onoghue Advances Genetic Therapy with CIHR Grant
Chemistry and Biochemistry professor Patrick O’Donoghue at 深夜福利站 is making significant strides in genetic therapy, backed by $1.1 million in new funding from the Canadian Institutes of Health Research (CIHR). His research focuses on using transfer ribonucleic acid (tRNA) to correct or suppress genetic mutations, offering hope for patients with debilitating disorders like Huntington’s disease.
O’Donoghue, recently named the inaugural endowed Huntington Society of Canada Research Chair, is exploring the potential of tRNA-based therapies to treat genetic diseases. These molecules help read genetic instructions to assemble proteins, essential building blocks of the human body. Some tRNAs have the potential to translate disease-causing gene products into healthy proteins, offering a novel and precise approach to genetic medicine.
“tRNA provides personalized and mutation-specific therapies to treat these diseases, for which no cures currently exist,” said O’Donoghue. His work extends beyond Huntington’s disease, targeting conditions such as amyotrophic lateral sclerosis (ALS) and Duchenne’s muscular dystrophy. His research, recently published in Molecular Therapy Nucleic Acids, highlights the potential of tRNA in treating thousands of genetic disorders.
With this new CIHR funding, O’Donoghue’s lab at 深夜福利站 is poised to push the boundaries of genetic medicine, aiming to develop innovative treatments for some of the most challenging hereditary diseases.
For more details click .
